141 related articles for article (PubMed ID: 16187089)
21. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
[TBL] [Abstract][Full Text] [Related]
22. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1.
Romero P; Pannetier C; Herman J; Jongeneel CV; Cerottini JC; Coulie PG
J Exp Med; 1995 Oct; 182(4):1019-28. PubMed ID: 7561675
[TBL] [Abstract][Full Text] [Related]
23. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
[TBL] [Abstract][Full Text] [Related]
24. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
[TBL] [Abstract][Full Text] [Related]
25. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
Zhang Y; Chaux P; Stroobant V; Eggermont AM; Corthals J; Maillère B; Thielemans K; Marchand M; Boon T; Van Der Bruggen P
J Immunol; 2003 Jul; 171(1):219-25. PubMed ID: 12817001
[TBL] [Abstract][Full Text] [Related]
26. Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.
Marchand M; Brasseur F; van der Bruggen P; Coulie P; Boon T
Dermatology; 1993; 186(4):278-80. PubMed ID: 8513199
[TBL] [Abstract][Full Text] [Related]
27. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
28. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
[TBL] [Abstract][Full Text] [Related]
29. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.
Coulie PG; Karanikas V; Colau D; Lurquin C; Landry C; Marchand M; Dorval T; Brichard V; Boon T
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10290-5. PubMed ID: 11517302
[TBL] [Abstract][Full Text] [Related]
30. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.
Rivoltini L; Loftus DJ; Squarcina P; Castelli C; Rini F; Arienti F; Belli F; Marincola FM; Geisler C; Borsatti A; Appella E; Parmiani G
Crit Rev Immunol; 1998; 18(1-2):55-63. PubMed ID: 9419448
[TBL] [Abstract][Full Text] [Related]
31. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
32. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T
Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731
[TBL] [Abstract][Full Text] [Related]
33. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
[TBL] [Abstract][Full Text] [Related]
34. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
Germeau C; Ma W; Schiavetti F; Lurquin C; Henry E; Vigneron N; Brasseur F; Lethé B; De Plaen E; Velu T; Boon T; Coulie PG
J Exp Med; 2005 Jan; 201(2):241-8. PubMed ID: 15657293
[TBL] [Abstract][Full Text] [Related]
35. New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells.
Kobayashi T; Lonchay C; Colau D; Demotte N; Boon T; van der Bruggen P
Tissue Antigens; 2003 Nov; 62(5):426-32. PubMed ID: 14617050
[TBL] [Abstract][Full Text] [Related]
36. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer.
Chaux P; Vantomme V; Coulie P; Boon T; van der Bruggen P
Int J Cancer; 1998 Aug; 77(4):538-42. PubMed ID: 9679755
[TBL] [Abstract][Full Text] [Related]
37. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
[TBL] [Abstract][Full Text] [Related]
38. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
39. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.
Sartorius R; Pisu P; D'Apice L; Pizzella L; Romano C; Cortese G; Giorgini A; Santoni A; Velotti F; De Berardinis P
J Immunol; 2008 Mar; 180(6):3719-28. PubMed ID: 18322177
[TBL] [Abstract][Full Text] [Related]
40. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
